Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › ribociclib

ribociclib

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of ribociclib

17 trials tracked of ribociclib: 5 in phase 3 or 4 and 5 with published results. The most-cited published study has 703 citations.

17Trials tracked
5Phase 3 & 4
0Recruiting
5With published results
Phase distribution
Phase 3 5 Phase 2 9 Phase 1 3
  1. Phase 3 Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer Completed · 703 cited
  2. Phase 3 Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Completed · 261 cited
  3. Phase 3 Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. Completed · 89 cited
  4. Phase 3 Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer Completed · 37 cited
  5. Phase 3 Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC Completed · 35 cited
  6. Phase 2 LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC Completed
Show 11 more trials
  1. Phase 2 Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. Completed
  2. Phase 2 An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. Completed
  3. Phase 2 Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer Completed
  4. Phase 2 Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer Completed
  5. Phase 2 Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer Completed
  6. Phase 2 Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer Completed
  7. Phase 2 Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer Completed
  8. Phase 2 Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin Completed
  9. Phase 1 TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer Completed
  10. Phase 1 A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection Completed
  11. Phase 1 Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors Completed

Showing the 17 most-cited and recently-updated of 17 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Signet ring morphology in gastric biopsies may mask metastatic invasive lobular carcinoma from breast cancer
Oncology Sys. Review
Signet ring morphology in gastric biopsies may mask metastatic invasive lobular carcinoma from breast cancer Expert Review Helps Identify Breast Cancer Spreading to Stomach
This case report describes a 52-year-old woman with metastatic invasive lobular carcinoma that was initially misidentified as primary gastri…
A single patient's case shows how specific lab tests can help doctors distinguish between stomach cancer and metastatic breast cancer.
Frontiers Jun 12, 2026
CDK4/6 inhibitors show therapeutic potential in advanced gastrointestinal cancers, review finds
Infectious Disease Sys. Review
CDK4/6 inhibitors show therapeutic potential in advanced gastrointestinal cancers, review finds CDK4/6 inhibitors show promise against digestive cancers
This narrative review examines the role of CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) in advanced gastrointestinal cancers. It…
New review reveals how CDK4/6 drugs might work against stomach, colon, and liver cancers, but hurdles remain.
Frontiers Jun 5, 2026
Meta-analysis of CDK4/6 inhibitor rechallenge shows improved progression-free survival in advanced breast cancer
Oncology Meta-analysis
Meta-analysis of CDK4/6 inhibitor rechallenge shows improved progression-free survival in advanced breast cancer Switching drugs offers hope for advanced breast cancer patients facing treatment failure
This meta-analysis synthesizes data from phase II and III clinical trials involving 1396 patients with hormone receptor-positive, HER2-negat…
A large review found that restarting a specific cancer drug after stopping it can delay disease growth by nearly two months compared to stan…
May 28, 2026
CDK4/6 inhibitors plus endocrine therapy improve survival in advanced hormone receptor-positive breast cancer
Oncology Meta-analysis
CDK4/6 inhibitors plus endocrine therapy improve survival in advanced hormone receptor-positive breast cancer CDK4/6 Inhibitors Boost Survival In Advanced Breast Cancer
This meta-analysis of 11 phase 3 trials involving 6035 patients demonstrates that CDK4/6 inhibitors combined with endocrine therapy signific…
New data shows adding CDK4/6 inhibitors to hormone therapy helps patients live longer with advanced breast cancer.
May 1, 2026